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Summary 
Bone marrow of both normal and rearrangement-deficient mice contains a small population of 
B220(CD45R) + cells,  which do not express the B  lineage marker CD19.  Instead, part of this 
population coexpresses the surface marker CD43 and lacks or expresses very low levels of heat 
stable  antigen  (HSA)  and  BP-1,  thus  representing  a  part  of Hardy's  fraction  A  (B220  +- 
CD43+HSA -,  BP-1-)  of B  lineage  development.  However,  some 20-40%  of these  B220 +- 
CD19- cells also coexpress the NKI.1  surface molecule and do not express genes like Vp~B or 
B29 restricted to the B cell lineage. These cells  respond to recombinant interleukin  2 in vitro, 
and develop into killer cells that can lyse the prototypic NK target tumor cell, YAC-1, as well 
as syngeneic nomaal lipopolysaccharide or concanavalin A  blasts,  providing they lack the sur- 
face  expression  of major  histocompatibility  complex  class  I  molecules.  The  implications  of 
these findings for studies on B lymphopoiesis are discussed.  It is suggested that the CD19-spe- 
cific monoclonal antibody is more reliable,  as in humans,  than B220(CD45R)  to detect B lin- 
eage cells in mice. 
I 
n  the  mouse,  B  lineage  cells  express  the  surface  marker 
.B220(CD451L)  (1).  From  the  earliest  identified  c-kit + 
pro-B  cell  in  fetal  liver  and  bone  marrow,  all  the  way 
through the mature slgM+slgD + peripheral B cell as well as 
activated B  cell blasts,  all  B  lineage  cells  express the  B220 
marker often in upregulated forms. Only at the latest stage 
of B cell development, the fully differentiated plasma cell, is 
B220 downregulated. Even in recombinase-deficient (SCID 
and RAG-T) mice, the B220 surface marker is expressed on 
early progenitors  (2-4).  Therefore,  B220(CD45R)  is  com- 
monly used as a pan-B cell marker for studies in the mouse. 
In humans, however, another cell surface molecule, CD19, 
is used as a pan-B cell marker,  since reagents specific for a 
possible B220-1ike isoform of human CD45R do not exist 
(5,  6).  We  have  used  a  newly generated  mAb specific for 
murine CD 19 to compare the expression of B220 with that 
of CD19 on cells  of bone marrrow of normal as well as of 
rearrangement-deficient  (RAG-2T) 1 animals.  We  identify 
IAbbreviations used in  this paper: BDF,  (C57BL/6 X DBA/2)FI: J3:mT 
mice, B  2 microglobulin-deficient nfice; HSA, heat stable antigen; RAG- 
2T  mice, recombinase-activating gene 2-deficient nfice; RT,  reverse 
transcriptase. 
here  a fraction of bone marrow B220 + cells  that  does not 
express  CD19  and does not belong to cells  committed to 
the B lineage, but that has both phenotypic and functional 
properties of NK cell precursors. 
Materials and Methods 
Mice.  4-5-wk-old fen~tle BALB/c, C57BL/6 and (C57BL/6 X 
DBA/2)F1  (BDF0  mice  were  purchased  from Biological  Re- 
search  Laboratories,  Ltd.  (Ftillinsdorf,  Switzerland).  RAG-2T 
mice  (4)  originally  obtained  from Dr.  F.  Alt  (The  Children's 
Hospital,  Boston,  MA) and B  2 microglobulin~deficient (B2MT) 
mice (7) originally  obtained from Dr. R. Jaenisch (Massachusetts 
Institute  of Technolog% Cambridge, MA) were bred in our own 
animal facilities. 
Antibodies.  The FITC-, PE- and APC-labeled mAb RA3.6B2 
(anti-CD45R, B220), the biotin-, FITC- or PE-conjugated mAbs 
145-2C1 l (anti-CD3-e-chain), RM4-5 (anti-CD4), M1/70 (anti- 
CD11b [Mac-I]), J11d (anti-CD24 [heat stable antigen]  [HSA]), 
7D4  (anti-CD25  [TAC,  IL-2R cx-chain]),  2.4G2  (anti-CD32/ 
CD16 [Fc'yll/IlIR]), $7 (anti-CD43),  TM-I31 (anti-CD122  [IL-2R 
[3-chain]), 6C3 (anti-BP-1), PK136 (anti-NKl.1),  2B4 (anti-NK 
cells) and 5E6 (anti-NK cells) were all obtained from PharMingen 
(San Diego, CA). The mAbs ACK  4 (anti-c-kit)  (8), A7R34 (anti- 
IL-7R) (9), and 1D3 (anti-CD19, see below) are lgG of rat origin 
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G-Sepharose  columns  (Pharmacia,  Uppsala,  Sweden)  as  recom- 
mended by the supplier. They were FIT(] or biotin labeled accord- 
ing  to  standard  procedures.  FITC-conjugated  goat  anti-mouse 
lgM  and  streptavidin-PE  were  purchased  from  Southern  Bio- 
technology Associates (Birmingham, AL). 
Production qf Anti-CD I 9 mAbs.  The  human  erythroleukemia 
cell K562  was  transfected  (10)  with expression vector pZipNeo 
containing the  full-length eDNA encoding  murine  CD19  (11). 
G418-selected K562 cells expressing high levels ofmurine CD19 
were used to irmnunize Lewis rats,  from which hybridomas were 
produced  after  fusion  of splenocytes  with  NS-1  myeloma  cells 
following standard  procedures.  One  clone,  1D3,  is  a  rat  IgG2~K 
and was selected for its ability to bind murine CDl9-transfected 
K562, but not wild-type K562, cells. The antibody inununoprecip- 
itates  the expected protein of 110 kD from transfected cells (12). 
Flow Cytometry.  Flow cytometric analyses  were performed as 
described  below  (13,  14).  For  cell  sorting,  bone  marrow  cells 
were  stained  with  APC-labeled  B220  together  with  biotin- 
labeled  anti-CDl9  revealed  by  PE-streptavidin.  Stained  cells 
were resuspended  in PBS containing 2% FCS and  1 lxg/ml pro- 
pidium iodide (Sigma Chemical Co., St.  Louis, MO)  to exclude 
dead cells by gating in FL3 as described (15).  Sorted cells were ei- 
ther used tbr in vitro cell culture  or for further flow cytometric 
analyses.  For in vitro cell culture,  B220+NKl.1 §  B220*CD4 +, 
and  B220+CD19  NKI.I  CD4-  cell  populations  were  sorted. 
Therefore,  bone  marrow  cells were  stained  with  FITC-labeled 
anti-B220  together with either PE-conjugated anti-NKl.1,  PE- 
conjugated anti-CD4, or a cocktail of PE-conjugated anti-NK1, l, 
anti-CD4, and anti-CD 19. Sorted cell populations were routinely 
reanalyzed and showed  >95%  purity  in all experiments showed 
herein. Cell sorting was performed on a FACStar  |  (Becton Dick- 
inson &  Co.,  Mountain  View, CA), while a FACScan  '~ (Becton 
Dickinson & Co.) was used tbr flow cytometric analyses. 
Cell Culture and Generation qf LdK Cells.  All cell  cultures  were 
performed using IMDM  (GIBCO-BP,,L,  Life Technologies Ltd., 
Paisley,  Scotland)  containing  1￿  nonessential  anfino  acids,  1￿ 
kananwcin  (both from GIBCO-BILL), 5  ￿  10 -5 M  [3-mercapto- 
ethanol (Fluka AG, Buchs, Switzerland), 5 txg/ml porcine insulin 
(Sigma Chemical Co.), 0.03% Primatone P,L (Quest Interuational, 
Naarden,  The Netherlands),  and 2% FCS (GIBCO-BR.L) as de- 
scribed earlier (16).  For the generation of LAK cells,  sorted cells 
were plated at  l0  s cells/ml m  1 nil culture medium supplemented 
with  103  U/nil  of  rlL-2  obtained  from  a  transfected  X63- 
Ag8.653 cell line (17) generated in our laboratory. After 5 d of cul- 
ture, cells were harvested, washed, and counted for subsequent use 
either in  FACS analyses  or 5~Cr  release  assays. The  recovery, of 
rIL-2-activated NK1.1-  cells after 5 d was generally 1{>20 times 
the number of input cells. 
Preparation qf NK Targets and S~Cr Releaser Assay.  Target  cells 
from  nomaal  or  13~mT mice  were  prepared  by culturing spleen 
cells at  106 cells/ml in the presence of 2  btg/ml of Con A (Phar- 
macia)  or 20  ~g/nfl of LPS  (from Escherichia coli EH100,  kindly 
provided by Dr. C.  Galanos,  Max Planck  Institute tbr hnmuno- 
biology, Freiburg,  Germany).  After 2 d, the cells were harvested 
and enriched for viable blast  cells by centrifugation onto a cush- 
ion of Ficoll-Paque (Phamlacia)  according to the instructions  of 
the manufacturer.  Spleen  cell blasts  as  well as  YAC-1  Moloney 
leukemia virus-induced lymphoma cells (18) were adjusted to 1{)  7 
cells/nil in medium containing FCS, of which 100  I~1 was labeled 
with 1 mCi ofsodium-Slchromate (CJS 4, sp. act.  12.5 GBq/mg; 
Amersham  Life Science, Amersham,  UK)  tbr  2  h  at  37~  (19). 
Atier three washes with prewarmed medium,  labeled target cells 
were counted and concentrations adjusted to  l0  s cells/ml. Target 
cells were distributed  in 50-1xl  aliquots  (5,000  targets/well)  into 
wells  of V-bottom  microtiter  plates,  which  previously  had  re- 
ceived 50-btl replicas containing twofold dilutions in medium of 
effector cells so as to obtain different E/T cell ratios. To allow im- 
mediate contact between targets and effector cells, plates were spun 
for  1 rain at  1,000  rpm  followed by a  4-h  incubation  period at 
37~  After incubation, plates were spun at  1,200 rpm for 5 min, 
and 50  txl of supernatant  was aspirated  for counting in a ganuna 
counter  (Cobra  5010;  Packard  Instrument  Company,  Meriden, 
CT).  Specific lysis was calculated as % specific lysis  =  (E -  S)/ 
(T -  S) ￿  100,  where E was the experimental StCr release, S was 
the count released when target cells were cultured alone,  and  T 
was the total counts contained in the target. SD of triplicate sam- 
pies never exceeded 2.5%. 
Limiting Dilution of Sorted Bone Marrow Cells.  After sorting bone 
marrow cells into B220+NKl.1 ~, B220+CD4 +, and B220+CDI9 -- 
CD4- cells,  threefold dilutions of cells in 200 1~1 of medium con- 
taining  103  U/ml of rlL-2 were cultured in wells of round-bot- 
tom microtiter plates at 37~  in a  10%  CO2/air atmosphere.  48 
cultures were set up with each dilution of sorted cells.  After 5 d of 
incubation,  all cultures received 25  t*1 of medium containing an 
average of three YAC-I  lymphoma cells.  Plates were spun  for 1 
nfin at  1,000  rpm and incubated for an additional  10 d.  Cultures 
containing growing YAC-I  cells were then scored by visual in- 
spection and considered not to have contained any cell capable of 
developing into lytic NK cells.  In  control  cultures,  initially not 
containing any  bone  marrow  cells,  YAC-I  cells plated  at  three 
cells/culture  showed  growth  in  >95%  of the  wells.  The  fre- 
quency of functional NK cells responding to rIL-2 was calculated 
according to Poisson's distribution. 
Isolation qf Ra\M and Reverse Transcriptase PCR.  Total RNA for 
cDNA synthesis  was  prepared  from different fractions of freshly 
sorted bone marrow cells as well as 5-d cultured LAK cells using 
RNAzol B  (Biotecx Laboratories,  Inc., Houston,  TX) according 
to the manufacturer's recommendations,  iRA  was reverse-tran- 
scribed  using  Superscript  II  reverse  transcriptase  (R.T;  GIBCO 
Life Technologies, Gaithersburg,  MD),  1 mM dNTPs,  1 ~g ran- 
dom  hexanleric  oligonucleotides,  and  the  supplied  RT  buffer. 
PCR  assays were  carried  out  using  the  following primer  pairs: 
[3-actin  (20):  5'  GAA GTC TAG AGC AAC ATA GCA CAG 
CTT CTC 3', 5' GTG GGA ATT CGT CAG AAG GAC TCC 
TAT GTG 3': Vp~B (21):  5' GTC TGA ATT CCT CCA GAG 
CCT AAG ATC CC 3', 5' CAG GTC TAG AGC CAT GGC 
CTG  GAC  GTC  TG  3';  B29  (22):  5'  TAA GTC  TAG  AAG 
TTC CGT GCC ACA GCT GTC 3', 5' CAC TGA ATT CCC 
AAG GAA GCC  CTT  GTT  CCC  3';  perforin  (23):  5'  ACC 
GAT  GCT  GAC  CTG  GGC  CTC  3',  5'  AGG  TTC  CTG 
AGG CCT GAC CGC 3'. Amplification of the cDNA was car- 
ried out with  1 cycle at 94~  for 30  s followed by 3{) cycles at 
94~  for 20  s,  55~  tbr 20  s,  and  72~  for 60 s.  The  expected 
sizes  of the  PCt~-  products  are  535  bp  fbr  [3-actin,  400  bp  fbr 
VpreB  , 320 bp fbr B29,  and 610 bp for perforin.  P,T-PCR prod- 
ucts were electrophoresed  through  a  1% agarose  gel and  visual- 
ized by UV light after ethidium bromide staining. In addition, af- 
ter  electrophoresis,  the  products  of  the  perforin  PCR.  were 
analyzed by Southern blotting after transfer to a Genescreen Plus 
(NEN Dupont,  Boston,  MA) membrane in 0.4 M  NaOH.  After 
neutralization with 0.2  M  phosphate  butter (pt-I  7.2)  and prehy- 
bridization  at  42~  for 4  h,  the membranes  were  hybridized  at 
42~  overnight with a ~2P-labeled oligonucleotide probe (proto- 
col and probe kindly provided by Dr. H.-P-. 1Lodewald, Basel In- 
stitute  for lmmunolog3',  Basel,  Switzerland).  Both  prehybridiza- 
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Denhart's solution, and 0.1% SDS. Membranes were washed four 
times in 4  ￿  SSC, 0.1% SDS, at 42~  for 10 min and exposed to 
x-ray film (X-OMAT; Eastman Kodak Co., Rochester, NY). 
Results  and Discussion 
The Expression of B220(CD45R) and CD19 on Mouse Bone 
Marrow Cells.  A  mAb recognizing mouse  CD19  has been 
used  to  identify cells in the mouse bone marrow  that  ex- 
press  this B  lineage-related  surface  marker.  Double  stain- 
ing,  together  with  an  antibody directed  against  the  other 
mouse  B  lineage-related  surface  marker  B220(CD45R), 
identified three  populations in FACS  |  analyses of normal 
BDF 1  bone  marrow:  B220-CD19-  cells,  B220+CD19 + 
ceils, and B220+CD19 -  cells. No B220-CD19 + cells could 
be detected by FACS  |  analyses (Fig. 1). The B220+CD19 + 
cells in normal mouse bone marrow contain all the cells be- 
longing to  different stages  of B  cell development,  that  is, 
c-kit+CD43+CD25 -  pro-pre-B-I  cells (14),  c-kit-CD25 + 
pre-B-II cells (24,  25),  sIgM+IgD -  immature B  cells, and 
sIgM+IgD + mature B  cells (26)  (data not shown). Thus, all 
B  lineage-committed cells in normal bone marrow identi- 
fied so far express both B220 and CD19. 
In bone marrow of RAG-2T  mice, the same three pop- 
ulations are found: B220-CD19-  cells, B220+CD19 + cells, 
and B220+CD19 -  cells  (Fig.  1).  Again, no B220-CD19 + 
cells  could  be  detected,  as  in normal bone  marrow.  The 
B220+CD19 + fraction of cells in RAG-2T  mice is reduced 
in  size  compared  with  bone  marrow  of  normal  mice, 
which is in agreement with a block of B  cell differentiation 
at  the  transitional stage from pro/preB-I  to  pre-B-II  cells 
due  to  the  rearrangement  deficiency.  The  size  of  the 
B220+CD19 -  fraction of cells in the RAG-2T  bone mar- 
BDF1  RAG-2 H- 
(3) 
E3 
o 
CD45R(B220) 
~:,;,:>~.  ~'~  :: 
CD45R(B220) 
Figure  I.  Both  normal  and  RAG-2T  bone  marrow  contain 
CD451K+(B220)CD19  -  cells. FACS  |  analyses of normal  BDF  1 and 
RAG-2T bone marrow  after double  staining for surface expression of 
CD45R(B220)CD19.  Biotinylated  anti-CD19 was  revealed  with  PE- 
streptavidin in conjunction  with FITC-labeled anti-B220. 
row  was  determined  and  compared  with  that  of normal 
mice.  Therefore,  bone  marrow  cells  pooled  from  five 
RAG-2T  mice and five age-matched  normal mice at dif- 
ferent times after birth (4, 10, and 15 wk) were analzyed. In 
all samples, independent of age and strain, 3-6% of all nu- 
cleated  bone  marrow  cells  were  B220+CD19 -  (data  not 
shown). 
Analysis of the Function(s) of B220 § CD 19-  Cells in Mouse 
Bone Marrow.  It  appeared  reasonable  to  expect  that  the 
B220+CD19 -  cell fraction in bone marrow  (Fig.  1)  could 
contain earlier B  lineage precursors,  before  the  expression 
of CD19.  Therefore,  we  used  culture  conditions similar 
to  those  used  for  cloning and  long-term  proliferation  of 
pro-pre-B-I  cells  (16),  that  is,  a  layer of stromal  cells and 
added recombinant cytokines, in an attempt to convert the 
B220+CD19 -  cells  to  B220+CD19 +  stromal  cell/IL-7- 
BDF1 
RAG-2-t- 
ra  I 
,  l  t  i~  16z  6.  t-  '  -lt*  le*''"  tl=  "  *r 
He 
BP-1  Control  CD43  CD24 (HSA)  NKI.1 
Figure 2.  FACS  |  analyses of sorted B220+CD19 -  bone marrow cells from BDF 1 and RAG-2T mice. Cells were double stained for B220 and CD19 
and subjected to cell sorting as described in Materials and Methods. The sorted cells were restained and analyzed by FACScan  |  for the surface markers 
CD43, CD24 (HSA), BP-I, and NK1.1, as described in Materials and Methods. Since the restaining was done using biotinylated antibodies revealed by 
streptavidin-PE, the control graphs indicate background staining with PE-streptavidin  only. 
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rlL-7,  and  rlL-10  were  tested  in  these  experiments  (17). 
IL-3, IL-5, [L-6, IL-7, and IL-10 did not change the phe- 
notype or reactivity of the B220+CD19 -  cells  in  the  ex- 
pected  way.  However,  to  our  surprise,  ceils  in  cultures 
containing rlL-2 or rlL-4 within 5 d developed into appar- 
ent killer cells,  destroying the coculture stromal cells.  This 
occurred  with  B220+CD19 -  cells  from bone  marrow  of 
both normal and RAG-2T mice,  excluding the participa- 
tion of conventional cytotoxic T  killer cells. 
This prompted an examination of the expression of addi- 
tional markers on sorted B220+CD19 -  bone marrow cells. 
In Fig.  2,  part  of the  extra  markers  expressed  on B220 +- 
CD19-  cells  in the  bone marrow of BDF 1 and  RAG-2T 
mice are shown.  In both strains,  these  cells  express  CD43 
but  not or only low levels  of CD24  (HSA)  and  no BP-1 
(Fig. 2) and therefore might contain cells defined by Hardy 
et al.  (28)  as fraction A  in their scheme of B  cell develop- 
ment.  About  20-40%  of the  B220+CD19 -  cells  in  the 
bone marrow of both BDF 1 and RAG-2T mice express the 
NK cell-related marker NK1.1 (29). This marker is not de- 
tectable on the B220+CD19 + cells  (data not shown).  The 
number of B220+NKI.1 + cells  was in several experiments 
slightly  higher  (maximally  twofold)  in  RAG-2T  mice 
compared with age matched normal mice (see Fig. 2). 
Sorting the B220+CD19-NK1.1 + and the B220+CD19 -- 
NK1.1- populations and subsequently analyzing their IL-2 
reactivity revealed that only the B220+CD19  NK1.1+, but 
not the  NKI.I-,  cells  developed  into  killer  cells  (see  be- 
low).  The B220+CD19-NK1.1 +  cells  lack the  expression 
of  CD25  (the  IL-2  receptor  ot  chain),  but  do  express 
CD122 (the IL-2 receptor 13 chain). 
After culture in rlL-2, these cells  remain B220+CD19 -- 
NKI.1 +,  but  lose  the  expression  of CD43  (Fig.  3).  They 
are  homogeneously large  and  granular  as  revealed by for- 
ward and sideward scatter analyses. All these cells coexpress 
the newly described NK cell surface marker 2B4  (30)  and 
low  levels  of CD122  (IL-2R  13  chain),  but  not  CD25 
(IL-2R o~ chain). A  fraction of the cells  express Mac-1  and 
another  NK  cell  surface  marker,  5E6  (31).  In  the  bone 
marrow of normal mice,  a  fraction of the  B220+CD19 -- 
NKI.1 +  cells  coexpress  CD3~,  and  their  relative  number 
stays  constant  during  culture  in  rlL-2.  Since  no  CD3~- 
expressing  B220+CD19-NKl.1 +  cells  are  present  in  the 
bone  marrow  of RAG-2T  mice,  these  cells  most  likely 
represent the previously described NKI.1 + T  cells  (32, 33). 
We conclude that by marker expression and morphology 
these  activated  B220+CD19-NKl.1 +  bone  marrow  cells 
are similar to NK cells found in the periphery and classified 
as LGL (34).  It has been shown previously that stimulation 
of spleen cells with IL-2 (35)  or IL-4 (36)  may generate lyti- 
cally active  NKI.1 +  cells  that  coexpress B220.  However, 
fresh  ex vivo, sorted B220+CD19-NKl.1 + bone marrow 
cells  do not cause lysis  of the  stroma cells  in a short-term 
assay,  nor do they kill classical  NK targets, like YAC-1  (see 
below).  We  were  concerned  that  the  anti-NKl.1  mAb 
(PK136)  used for sorting these  cells  would inhibit sponta- 
neous killer  activity,  as  has been reported  previously (37). 
Therefore,  freshly  isolated  total  bone  marrow  cells  from 
RAG-2T  animals  were  used  in  the  standard  51Cr  release 
assay.  At E/T  cell ratios up to 300:1  we observed no sig- 
nificant  lysis  of YAC-1  tumor  cells,  in  accordance  with 
previously  published  data  (38,  39).  Also,  in  assays  with 
rlL-2-activated NKI.1  cells,  addition  of up to  100  fxg/ml 
of PK136  mAb would  not inhibit  lysis  of YAC-1  tumor 
targets or normal LPS- or Con A-activated blasts  of 132mT 
origin. We emphasize,  though, that we used bone marrow 
of healthy, unmanipulated mice, whereas most other inves- 
tigators  demonstrating NK activity of cells  freshly isolated 
ex vivo used spleen  cells  from animals pretreated  with  in- 
terferon  inducers  like  polyinositol:polycytidine  (37)  or 
tilorone  (40).  It therefore  appears that the  5-d cell culture 
period in the presence of rIL-2 or rlL-4 differentiated  NK 
activity from more undifferentiated,  inactive precursor cells. 
A 
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Figure 3.  Cell  surface phenotype ofrIL-2-activated NKI.1 + bone marrow cells from BDF  / mice. Cells sorted into the B220+CD19-NKl.1 + fraction 
was cultured for 5 d in the presence of 103 U/ml ofrlL-2. Staining and FACScan  |  analyses were performed as described in Materials and Methods. 
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Figure 4.  A large fraction ofB220+CD19-NKI.1 - bone marrow cells 
express CD4. Bone marrow cells from normal BDF 1 and RAG-2T mice 
were sorted for B220+/CD19 -  cells as described in Materials and Meth- 
ods. The collected cells were restained with FITC-labeled anti-CD4 and 
PE-labeled anti-NKl.1 and analyzed by FACScan  | 
The subpopulation of the B220+CD 19-NK1.1-  cells in 
bone marrow that do not give rise to NK cells were further 
analyzed. As shown in Fig. 4  in both normal BDF1 as well 
as RAG-2T  mice, this population can be subdivided based 
on  the  expression  of CD4.  Thus,  ~50%  of the  B220 +- 
CD19-NKl.1-  cells express  CD4.  The level of CD4  ex- 
pression is comparable to that found on T  cells. Since these 
cells do not express CD3 or any other component of TCR 
(data  not  shown)  and  moreover  are  present  in  identical 
numbers in R_AG-2T mice, they are not B220 + T  cells. So 
far we have not observed any effects ofrlL-2, rlL-3, rlL-4, 
rlL-5,  rlL-6,  rlL-7,  or  GM-CSF  on  these  cells  in  vitro. 
Currently  the  potential  of these  cells  is  analyzed  by  "in 
vivo" transfer systems. 
The B220+CD19-NK1.l-CD4  -  population might con- 
tain some  early B  cell progenitors,  since preliminary RT- 
PCR  analyses revealed  low  expression  of ks,  VwB,  rob-1, 
and B29 genes in these  cells (data not shown).  Moreover, 
limiting dilution experiments showed that  1/100 to  1/200 
of these cells can form pre-B  cell colonies in the presence 
of rlL-7. Also, the potential of these cells is currently being 
analyzed by in vivo transfer systems. 
Most NK1. I +B220 +  CD 19- Cells Are Precursors of Classi- 
cal NK Cells and Respond to IL-2 by Development  into Clones 
of Cytolytic NK Cells.  Classical  NK  cells  kill  MHC  class 
I- target cells (40, 41), and are inhibited in their killing ac- 
tivity by the expression of MHC  class I molecules on target 
cells (42). Therefore, a variety of LPS- or Con A-activated 
spleen cells were used as targets in 51Cr release cytotoxicity 
assays. Syngeneic, semisyngeneic, or allogeneic targets from 
normal mice were  not significantly lysed by these  rlL-2- 
activated  NKI.1 +  cells at E/T  ratios  of 10:1  and  below. 
However,  when  Con  A-  or  LPS-activated  targets  were 
generated  from  [32mT  mice  lacking MHC  class  I  surface 
expression,  syngeneic and allogeneic targets  were  lysed to 
the same extent irrespective of whether the targets were of 
T  or B  cell origin, often reaching 30--60% specific lysis at 
E/T  ratios of I : 1 during the 4-h assay period (Fig. 5 a). Al- 
ways included in the 51Cr release assays was the prototypic 
NK  target  YAC-1,  which  typically showed  60-80%  spe- 
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Figure 5.  Sorted, rlL-2-activated  NKI.1 + cells kill the prototypic tar- 
get YAC-1 as well as normal targets lacking MHC class I expression, but 
do not kill normal targets expressing MHC class I. (a) Conventional 4-h 
51Cr release cytotoxic  assay performed  as  described  in Materials and 
Methods.  The  effectors were  derived  after 5 d  of culture  in rlL-2 of 
B220+CD19-NKl.1 + bone marrow cells sorted from normal BDF  1 ani- 
mals. The targets were YAC-1  (V-V), LPS blasts (Q, ") or Con A blasts 
(O, [53) from normal BALB/c  spleen (O, O) or BALB/c-132mT spleen 
(I, []). (b) Limiting dilution analyses of B220+CD19-NKI.1 + (O) and 
B220+CD19-NKl. I -  (O)  bone  marrow  cells sorted  from  RAG-2T 
mice. For each concentration of sorted cells, 48 microwell cultures were 
seeded. After 5 d of culture in the presence ofrlL-2 (10  3 U/ml), an aver- 
age of 3 YAC-1 cells were added to each culture, and the incubation was 
continued for an additional  10 d.  Cultures showing  clones of growing 
YAC-1 tumor cells were scored by visual inspection. The data points rep- 
resent the fraction of cultures showing growth  of tumor cells out of 48 
cultures seeded. 
cific lysis at similarly low E/T  ratios.  The fact that we ob- 
serve a plateau of specific lysis different for the tumor target 
compared  with  the  splenocyte targets  may be  due  to  our 
way of calculating the percentage of specific lysis: the total 
cpm  of SlCr  contained within the  targets  was  used  rather 
than attempting to determine total counts releasable by ar- 
tificial means using agents like SDS, NP-40, or acetic acid. 
These results support the conclusion reached by analysis of 
NKI.1  expression  that  the  cytotoxic  activity  developed 
from  B220+CD19-NKl.1  +  cells of bone marrow is con- 
veyed by NK cells. 
Since  only  60-80%  specific  SlCr  release  could  be  ob- 
tained in the  cytotoxic  assay using YAC-1  as a  target,  we 
devised a  method  to  determine the viability of the  tumor 
target cells by a test that measures their growth after contact 
with the effector  cells. For that purpose,  limiting numbers 
of YAC-1  targets  were  distributed  into  cultures  already 
containing  [L-2-activated  B220 +CD 19-NKI.1 +  effector 
191  Rolink et al. cells.  At estimated E/T ratios of 10-20: 1,  no YAC-1  tu- 
mor cells would grow out. This method was further used as 
a read-out system in limiting dilution analyses to determine 
the  frequency  of  sorted  B220+CD19-NKl.1 +  cells  re- 
sponding to rlL-2 by developing into clones of cells capa- 
ble of killing limiting numbers of YAC-1 tumor cells.  We 
observe straight lines in semilogarithmic plots scoring the 
number of cultures yielding growing YAC-1 target tumor 
cells against dilutions of previously added sorted cells stim- 
ulated for 5 d with rlL-2 (Fig. 5 b). According to Poisson's 
distribution, an average of one NK1.1 + cell is present in a 
culture and responds to rlL-2 when 37% of the cultures do 
not show any growing YAC-1  tumor cells.  From the re- 
covery of cells in our previous mass  culture experiments, 
we  can  expect  one  NKI.1 +  cell  responding to  rlL-2  to 
yield a clone of 10-30 cells after 5 d  of culture. As can be 
seen in Fig. 5  b, using limiting numbers of sorted B220  +- 
CD19-NK1.1 +  cells  added  to  rlL-2-containing cultures 
for 5  d  before adding the YAC-1  cells,  an average of five 
NKI.1 + cells have to be plated in order to achieve that de- 
gree oftumoricidal effect. Thus, the NKI.1 + cells respond 
to rlL-2 and develop into clones of NK cells with lytic ca- 
pability. In contrast, sorted B220+CD19-NKl.1  cells did 
not give rise to cytolytic cells (Fig. 5  b), even when plated 
at 104 cells/well (data not shown). 
B 2 2 0 +  C D 19-NK1.1 + Cells Lack Expression  of Genes Spe- 
cificforB  Celt Lineages.  Bone  marrow  cells  from  RAG-2T 
animals were sorted into B220+CD19 + and B220+CD19  - 
NKI.1 +  cells.  In  addition,  NKI.1 +  cells  were  activated 
into killer cells by culture for 5 d in the presence of rlL-2. 
Figure  6.  Expression of  mRNA  for 
VpreB ,  B29,  and  perforin  in  sorted 
B220+CD19  +, B220+CD19-NK1.1  +, and 
rlL-2-stimulated  B220  +CD 19-NK1.1  + 
cells from bone marrow of RAG-2T ani- 
mals. Total RNA isolation  and RT-PCR 
assays were performed as described in Ma- 
terials and Methods. Different dilutions  of 
cDNA were subjected to PCR amplifica- 
tion specific for ~-actin, VpreB  ,  B29, and 
perforin. Dilutions of the resulting prod- 
ucts were separated by electrophoresis on 
a 1% agarose gel containing  ethidium bro- 
mide and visualized  by UV light illumina- 
tion (A). In addition, the products of the 
PCR assay for perforin were blotted and 
hybridized with an internal probe of the 
following sequence: 5' AGG CCA GAG 
GCA AAC ATG CG 3' specific for per- 
forin (B). 
RNA was extracted from fleshly sorted as well as cultured 
cells.  Subsequently, expression of mRNA  for VpreB, B29, 
and perforin was analyzed by RT-PCR. A variety of oligo- 
nucleotide primers spanning an intron-exon boundary de- 
scribed in Materials and Methods were used. As can be seen 
in Fig. 6, only the B220+CD19  + and not the B220+CD19 -- 
NK1.1 + or the rlL-2-activated B220+CD 19-NK1.1 + cells 
express  the  B  cell  lineage  marker  Vere/3 and  B29  genes, 
whereas only rlL-2-activated, not freshly isolated NK1.1+, 
cells express abundant levels of perforin mRNA, a  distin- 
guishing marker for mature cytolytic T  and NK cells (23). 
Conclusions.  The data presented here show that not all 
B220 +  cells  belong  to  the  B  cell  lineage.  Within  the 
B220+CD19 -  cells at least three subpopulations can be dis- 
tinguished. The first, expressing NKI.1, has been identified 
here in detail to be the precursor of NK cells.  This cell is 
likely  to  be  a  product  of an  earlier  NKI.1-  precursor, 
which,  upon transplantation, develops  into  NKI.1 §  cells 
capable  of hybrid resistance  (43).  The  second,  expressing 
CD4,  has  a  potential and/or  function that  is  so  far  un- 
known.  Within  the  third  group  of  cells,  which  are 
NKI.I-CD4-,  are  those  that,  upon  culture  on  stromal 
cells and IL-7,  form pre-B  colonies. Precursors  for  other 
blood  cell  lineages  might  also  be  contained within  this 
group of cells, but attempts to clone them with the appro- 
priate cytokines have so far failed. All of these B220  + sub- 
populations of cells  express CD43 and are low or negative 
for HSA and BP-1  expression, markers that define fraction 
A in Hardy et al.'s (28)  scheme of B  cell differentiation. 
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